Coty Inc.

▲ Bull Case

• ◆Fragrance structural tailwind + defensible scale moat: Global fragrance TAM is growing 7.4% CAGR (2026-2031) vs. 5% beauty overall. COTY's #2 position (~$3.7B of ~$78B category) creates superior perfumer relationships, retailer leverage, and license-renewal economics. Post-divestiture, prestige fragrance would comprise ~80%+ of revenue; EBITDA margins would expand to 21-23% (vs. current consolidated 18.4%), and COTY would trade closer to IPAR's 12-14x multiple, justifying $8-10/share base case.
• ◆Consumer Beauty divestiture at fair value unlocks value and simplifies equity story: Strategic review likely yields sale at 8-10x EBITDA (~$1.7-2.2B proceeds), spin-off, or partnership. Any outcome removes the drag of negative-LFL mass color cosmetics (-10% in Q3 FY26) from consolidated narrative. Proceeds flow to balance-sheet de-risking (toward 2.0x leverage) or shareholder returns (dividend reinstatement, buyback, special dividend). Net effect: ~$1-2/share accretive to COTY common equity in bull case.
• ◆Management credibility + stable controlling shareholder + no showstoppers: CEO Sue Nabi (ex-L'Oréal Paris Worldwide President) bought ~272.5k shares open-market in Aug 2025 at $5.50-6.50/share—above current $3.74 spot—and has not sold since hire (strong confidence signal). Executed Wella monetization on schedule, reduced leverage 8x→3.2x, and willingly put Consumer Beauty under strategic review. JAB's 50% controlling stake is a long-horizon family-office stability anchor.

▼ Bear Case

• ◆License portfolio concentration risk is the thesis killer: Prestige revenue (~$3.7B) is concentrated in 5-6 designer-house licenses (Burberry ~$700M, Hugo Boss ~$400M, Calvin Klein ~$300M, Gucci ~$200M, others). Loss of Burberry or Hugo Boss to a competing operator (Puig, L'Oréal Luxe) at renewal would eliminate 30-40% of prestige base, compress EBITDA by $200-300M, and force multiple compression back to 5-6x on reduced scale.
• ◆Consumer Beauty divestiture execution risk: Strategic review was announced Sept 2025 with end-2026 expected timing. Large portfolio carve-outs routinely slip 6-12 months due to buyer negotiations, valuation disagreements, or regulatory complexity. If divestiture is delayed into 2027 or abandoned, COTY permanently re-rates as a slow-growth conglomerate at 5-6x EBITDA, implying $2.50-3.00/share downside.
• ◆Tariff margin compression + travel-retail recovery uncertainty could reset gross margin lower: US tariffs on EU prestige fragrance persist through at least CY26; company guides -100 to -200 bps gross-margin compression in Q4 FY26. If tariffs extend beyond FY26 or can't be removed from cost structure, gross margin could structurally reset from historical 65%+ to 60-62%, permanently shaving ~200-300 bps from EBITDA margins.

“Consensus Street view (embedded in current 7x EBITDA multiple): COTY is a slow-growth conglomerate (~3-4% LT organic growth) with secular mass-color decline offsetting prestige fragrance strength; Consumer Beauty strategic review is real but timing/valuation uncertain with only ~30-40% probability of near-term success embedded; Consensus FY26 EPS $0.28 reflects skepticism; Analyst PT median ~$5-6 with range $4-7. Non-consensus / variant view (the bull case): September 2025 strategic review fundamentally changes COTY's terminal form from fragrance-led conglomerate (7x) to focused prestige-fragrance pure-play (12-14x IPAR analogs); Fragrance category growth (7.4% CAGR) is structural, not cyclical; Consumer Beauty divestiture is higher-probability than Street prices (~60-70% vs. 30-40%); management confidence signals are credible. The core disagreement: Does Consumer Beauty divestiture execute by end-2026 at fair value? Street is ~60-70% skeptical; the bull case is ~60-70% confident. This binary drives all equity dispersion.”

• ◆Q1 FY27 earnings print (late Aug 2026): Post-tariff comparison + ME recovery signal. Pass threshold: LFL +1%-+3%, Prestige +0%-+2%, maintain/raise EPS guide to $0.45+. Validates inflection thesis; multiple inflates 8-9x.
• ◆Consumer Beauty strategic-review formal announcement (target: end-CY2026 / Q3 FY27): Announced divestiture/spin-off at ≥8x EBITDA with clear timeline and pro forma bridge. 15-25% immediate re-rating; multiple moves to 10-11x; validates bull case.
• ◆Q1 FY28 earnings (late Aug 2027): Pro forma FY28E EBITDA margin guide 21-23%, Prestige LFL +2%-+4%, no license-loss signals, tariff fully passed. Bull thesis locked in; 12-14x multiple justified; $8.50+ validated.
• ◆License renewal data points (rolling 2027-2030): Marc Jacobs or Calvin Klein renewals extended at stable/improved terms; no competitor-bidding rumors. Moat durability confirmed; multiple sustains 12-14x; 5-10 year thesis extension.
• ◆Balance-sheet milestone: leverage 2.0x target (CY27 close): Achieve ≤2.2x net leverage; FCF conversion >65%; management signals shareholder-return optionality (dividend, buyback, special dividend). Unlocks $1B+ optionality; adds ~$0.50-0.75/share.

• ◆License non-renewal / competitive loss (Burberry, Hugo Boss, or Calvin Klein) — CRITICAL: Loss of Burberry or Hugo Boss = -$700M or -$400M revenue (-30-40% prestige base); EBITDA compresses $200-300M; multiple crashes to 5-6x; re-rate to $2.00-2.50/share. Single largest thesis-invalidator.
• ◆Consumer Beauty divestiture fails / extends beyond 2026 — HIGH: Delay into 2027 or formal abandonment = permanent re-rating to 5-6x conglomerate multiple; $2.50-3.00/share downside; credibility damage to Nabi; thesis invalidation.
• ◆Tariff margin compression persists / structural cost inflation unresolved — HIGH: If tariffs remain embedded, gross margin resets -200 to -300 bps permanently (62% vs. 65%); EBITDA margin falls to 16-17% vs. bull 21-23%; shaves 1-2x off multiple; $1.00-1.50/share downside.
• ◆China travel retail + Middle East recovery slower than expected — MEDIUM-HIGH: Travel retail negative through 2027 H1 = delays inflection by 2-3 quarters; extends deceleration narrative; multiple re-compression risk to 7x from 8x current.
• ◆Controlling shareholder (JAB) stake reduction >10% — MEDIUM: JAB trim removes stability anchor; likely triggers CEO search risk, portfolio revisit, or activist pressure; ~$0.50-1.00/share downside.